by ComplianceQuest

My Dashboard Inspection Tracker FDA Guidance Templates Assessments

Sign in Get started

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

ANALYTICS

Tracker Overview Enforcement Themes

FDA ACTIONS

Form 483s Warning Letters Inspections Recalls

AUDIT READINESS

COMPANIES

Companies Facilities

Loading…

Dashboard Warning LettersWarning Letter Details

MantroForce Warning Letter Details

Warning Letter

MantroForce

Room 701, Unit 127, 7/F Tower B New Mandarin Plaza Tsim Sha Tsui Hong Kong SAR China

Issue DateJune 17, 2026

FEI NumberN/A

Violations1

CountryChina

Issuing Office

Center for Drug Evaluation and Research (CDER)

Product Type

Drugs

Status

Open

Subject

Unapproved New Drugs/Misbranded

MantroForce FDA Warning Letter, June 17, 2026